Literature DB >> 19161563

Ten years of rizatriptan: from development to clinical science and future directions.

Richard J Hargreaves1, Chris R Lines, Alan M Rapoport, Tony W Ho, Fred D Sheftell.   

Abstract

The year 2008 marked the 10th anniversary since rizatriptan was first launched for the acute treatment of migraine. In this article we discuss the concepts that motivated the preclinical and clinical development of rizatriptan, the clinical evidence that has driven its use over the past decade, rizatriptan's overall contribution to the field, and future directions for research.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19161563     DOI： 10.1111/j.1526-4610.2008.01335.x

Source DB:  PubMed          Journal:  Headache        ISSN： 0017-8748            Impact factor:   5.887


  4 in total

Review 1.  Triptans for the management of migraine.

Authors:  Mollie M Johnston; Alan M Rapoport
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

2.  Rizatriptan for acute migraine headaches in adults.

Authors:  Rebecca Ling; Sheena Derry; R Andrew Moore; Henry J McQuay; Philip J Wiffen
Journal:  Cochrane Database Syst Rev       Date:  2010

3.  Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region.

Authors:  B Filipović; I Matak; Z Lacković
Journal:  J Neural Transm (Vienna)       Date:  2013-12-24       Impact factor: 3.575

4.  A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine.

Authors:  Lidia Savi; Stefano Omboni; Carlo Lisotto; Giorgio Zanchin; Michel D Ferrari; Dario Zava; Lorenzo Pinessi
Journal:  J Headache Pain       Date:  2010-08-05       Impact factor: 7.277
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.